- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04435158
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Study Following Multiple Subcutaneous Injections of SHR-1222 in Postmenopausal Osteoporosis Patients
This is a Multi-Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics, Immunogenicity with Multiple Subcutaneous Injections of SHR-1222 in Postmenopausal Osteoporosis Patients.
The primary objective of this study is to investigate the safety and tolerability of a range of subcutaneous SHR-1222 in postmenopausal osteoporosis patients. Secondary objectives are to determine the pharmacokinetics (PK), pharmacodynamics (PD) profile of SHR-1222 in postmenopausal osteoporosis patients including assessment of immunogenicity.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China
- 2nd Xiangya Hospital , Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent;
- Age ≥50 and ≤70 years old and post menopause for at least 5 years at the time of screening;
- Weight ≥40kg at the time of screening;
- BMD T-score ≤ -2.50 at the lumbar vertebrae, total hip or femoral neck at the time of screening, based on DXA scans;
- At least 2 vertebrae in the L1-L4 region and at least one hip are evaluable by DXA;
- Without disease that would significantly affect the study or bring additional health risks at the time of screening or baseline; blood pressure < 150 / 95mmHg, blood fasting blood glucose < 7.0mmol/l, glycosylated hemoglobin < 7%, or total cholesterol < 6.2mmol/l, triglyceride < 3.4mmol/l under the condition of lifestyle improvement rather than drug treatment; If there are other abnormalities in the examination report of the subject, the subject could only be included after investigator approval;
- Ambulatory.
Exclusion Criteria:
- Any disease affecting bone metabolism;
- Any severe (SQ3) or more than 2 moderate (SQ2) vertebral fractures, as assessed by the central imaging based on lateral spine x-rays at the time of screening;
- History of hip fracture;
- 25 (OH) vitamin D levels < 20 ng/mL at the time of screening. Vitamin D repletion will be permitted and subjects may be rescreened;
- BMD T-score < -3.50 at the lumber vertebra, total hip or femoral neck at the time of screening, based on DXA scans;
Use of the following agents affecting bone metabolism:
- IV bisphosphonates or denosumab prior to screening;
- Oral bisphosphonates, PTH analogs, Strontium or fluoride within 12m prior to screening;
- Hormone replacement therapy within 6m prior to screening;
- Glucocorticosteroids (inhaled or topical corticosteroids administered more than 2 weeks before the enrollment date are allowed), Anabolic steroids, Calcitriol and available analogues, thiazide diuretics within 3m prior to screening;
- History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of the results, such as hyperprolactinemia, osteosclerosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome;
- Hyperparathyroidism, hypothyroidism, hyperthyroidism, hypothyroidism, hypercalcemia, hypocalcemia, renal failure, etc at the time of screening;
- Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years;
- A clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar experimental drugs;
- Past medical history of cerebral infarction, ischemic or hemorrhagic stroke;
- Past medical history of Myocardial infarction, coronary heart disease, angina pectoris, heart failure (cardiac function II-IV), serious arrhythmia (such as atrial fibrillation, pacemaker needed)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic acyl transferase (GGT) or total bilirubin, more than 2 x ULN during screening;
- 3 months prior to screening involved in any drug clinical subjects (except screening failed or not given cinical drugs) or within 5 half-lives of test drug at the time of screening;
- Any major surgery in 1m prior to screening or a surgery plan during the study;
- Blood donation or loss more than 400mL or blood transfusion within 3 months prior to screening;
- Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive;
- No history of alcohol and substance abuse or positive urine drug screening;
- Subjects with any other situation should not be involved, which determined by the researchers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1:SHR-1222
Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
|
Pharmaceutical form: water injection Route of administration: subcutaneous injection
|
Experimental: Cohort 2:SHR-1222
Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
|
Pharmaceutical form: water injection Route of administration: subcutaneous injection
|
Experimental: Cohort 3:SHR-1222
Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
|
Pharmaceutical form: water injection Route of administration: subcutaneous injection
|
Experimental: Cohort 4:SHR-1222
Subcutaneous injection of SHR-1222 dosage 4 every 2 months × 6 months
|
Pharmaceutical form: water injection Route of administration: subcutaneous injection
|
Experimental: Cohort 5:SHR-1222
Subcutaneous injection of SHR-1222 dosage 5 every 2 months × 6 months
|
Pharmaceutical form: water injection Route of administration: subcutaneous injection
|
Experimental: Cohort 6:placebo
Subcutaneous injection of placebo × 6 months
|
Pharmaceutical form: water injection Route of administration: subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerance: Number of subjects with adverse events
Time Frame: Dose administration to 225 days after first dose administration
|
Number & proportion of subjects with adverse events
|
Dose administration to 225 days after first dose administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of PK parameter-time to maximum concentration (Tmax)
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PK parameter-maximum concentration (Cmax)
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PK parameter-area under curve (AUC)
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in serum C-telopeptide (sCTx) from baseline
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in aminoterminal propeptide type-1 procollagen (P1NP) from baseline
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in osteocalcin from baseline
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in bone-specific alkaline phosphatase (BSAP) from baseline
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in serum totol sclerostin
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in areal bone mineral density of lumbar spine (L1-L4) from baseline by dualenergy X-ray absorptiometry
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in areal bone mineral density of collum femoris from baseline by dualenergy X-ray absorptiometry
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Assessment of PD parameter-change in areal bone mineral density of total hip from baseline by dualenergy X-ray absorptiometry
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Antidrug antibody
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Neutralizing Antibody
Time Frame: Pre-dose to 225 days after first dose administration
|
Pre-dose to 225 days after first dose administration
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zhiguang Zhou, 2nd Xiangya Hospital of Central South University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-1222-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on SHR-1222
-
Second Xiangya Hospital of Central South UniversityCompletedOsteoporosis, OsteopeniaChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced MalignanciesAustralia, China
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAlzheimer's DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAsthma With Eosinophilic PhenotypeChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed HyperlipemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary HypercholesterolemiaChina